Back

Aspirin is out for primary prevention of cardiovascular disease - Discussion.

3 September 2019 (11:30 - 11:45)
Organised by:
Congress Presentation Part of: Controversies in antithrombotic treatment for primary and secondary prevention Cardiovascular Pharmacotherapy ESC Premium Access ESC Congress 2019

5 More presentations in this session

Presentation thumbnail
Aspirin is out for primary prevention of cardiovascular disease - PRO.
Professor J. Armitage (Oxford, GB)
Slides Video
Presentation thumbnail
Aspirin is out for primary prevention of cardiovascular disease - CON.
Professor C. Patrono (Rome, IT)
Slides Video
Presentation thumbnail
All patients with atherosclerotic disease should receive long-term intensified antithrombotic treatment beyond aspirin for secondary prevention - PRO.
Doctor J. Eikelboom (Hamilton, CA)
Slides Video
Presentation thumbnail
All patients with atherosclerotic disease should receive long-term intensified antithrombotic treatment beyond aspirin for secondary prevention - CON.
Doctor T. Cuisset (Marseille, FR)
Slides Video
Presentation thumbnail
All patients with atherosclerotic disease should receive long-term intensified antithrombotic treatment beyond aspirin for secondary prevention - Discussion.
Video

Access the full session

Session thumbnail
Controversies in antithrombotic treatment for primary and secondary prevention

The Event

Event poster

ESC Congress 2019

3 September 2019 11:30 CET
You may be interested in
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
thumbnail
ESC TV Today
Episode 7: Coronary spasm - Sex differences in heart failure
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources